profound: olaparib vs enzalutamide or abiraterone for mcrpc with hrr gene alterations
Published 4 years ago • 327 plays • Length 10:21Download video MP4
Download video MP3
Similar videos
-
6:39
profound: parp inhibitor olaparib compared with new hormonal agents in advanced castration resis...
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
0:53
dr. annunziata on olaparib and cediranib combination in ovarian cancer
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
1:32
dr. chang discusses the use of parp inhibitors in prostate cancer
-
2:19
phase iii results of olaparib for brca breast cancer
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
0:17
pipette 30ul x 25 bios013
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
0:41
understand the adverse events of parp inhibitors
-
2:43
phase i dose escalation of imc-f106c - first prame × cd3 immtac bispecific protein in solid tumors
-
2:34
vio® 100 c setup
-
1:49
parpi olaparib for the targeted treatment of metastatic prostate cancer
-
1:55
role of αvβ3 integrin in extracellular vesicle uptake by tumor cells
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
3:48
olaparib zytiga for metastatic castrate-resistant prostate cancer | learn about clinical trials
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact